MAA – pharmaceutical daily

July 13, 2017 Off

CTI BioPharma’s myelofibrosis drug one step closer to EMA’s approval

European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for CTI BioPharma’s pacritinib for the treatment of patients with myelofibrosis who have thrombocytopenia.

February 22, 2017 Off

Pfizer cancels listing in the UK, U.S. FDA accept Inotuzamab submition for ALL in adults

By Dino Mustafić

Pfizer has decided to cancel listing of its stocks from the UK listing Authority List. The company said on Wednesday it also cancels trading on the main London Stock Exchange market.

September 26, 2015 Off

Janssen’s daratumumab accepted for treatment of European patients with heavily pre-treated multiple myeloma

By Dino Mustafić

Janssen-Cilag International NV has announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European…